TG Therapeutics Inc (TGTX)

Debt-to-equity ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	100,118	71,135	66,788	7,716	28,970
Total stockholders’ equity	US$ in thousands	160,502	58,587	237,153	519,350	38,615
Debt-to-equity ratio		0.62	1.21	0.28	0.01	0.75

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $100,118K ÷ $160,502K
= 0.62

The debt-to-equity ratio of TG Therapeutics Inc has fluctuated significantly over the past five years, indicating varying levels of financial leverage and risk. In 2020, the ratio was very low at 0.01, suggesting a conservative capital structure with minimal debt relative to equity. This could signify strong financial stability and low risk exposure to debt obligations.

In 2021, the ratio increased to 0.28, indicating a moderate level of debt compared to equity. This could imply that the company took on additional debt to finance operations or investments during that period.

However, in 2022, the ratio significantly increased to 1.21, which suggests a substantial increase in debt relative to equity. This sharp rise in the ratio may raise concerns about the company's financial health and ability to manage its debt obligations effectively.

The most recent data for 2023 shows a decrease in the debt-to-equity ratio to 0.62. While still indicating a higher level of debt compared to equity, this reduction may reflect efforts by TG Therapeutics Inc to bring down its debt levels relative to equity.

Overall, the fluctuations in the debt-to-equity ratio of TG Therapeutics Inc over the past five years highlight the importance of closely monitoring the company's leverage and financial stability, as well as its ability to manage debt efficiently to mitigate potential risks.